Top Industry Leaders in the Paranasal Sinus Cancer Market
Latest Paranasal Sinus Cancer Companies Updates:
Roche: Received FDA approval for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of recurrent or metastatic paranasal sinus cancer.
AstraZeneca: Partnered with University College London to develop new AI-powered diagnostic tools for early detection of paranasal sinus cancer.
Elekta: Launched their Versa MaxTM radiotherapy system, offering advanced treatment planning and precision for tumors in the head and neck region.
Varian Medical Systems: Announced plans to expand their brachytherapy product portfolio with innovative solutions for paranasal sinus tumors.
Siemens Healthineers: Introduced their Biograph Aesthetix PET/CT scanner, designed for improved image quality and patient comfort in head and neck cancer imaging.
List of Paranasal Sinus Cancer Key companies in the market:
- AbbVie, Inc.
- Pfizer Inc.
- Eli Lily and Company
- Bristol-Myers Squibb Company
- Hoffman-La Roche Ltd.
- Becton, Dickinson and Company
- Novartis AG
- Ipsen Biopharmaceuticals Inc.
- Thermo Fisher Scientific
- Abbott
- G E Healthcare
- Agilent Technologies Inc.
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Bayer AG